<DOC>
	<DOCNO>NCT01259050</DOCNO>
	<brief_summary>The purpose study determine safety Zinc give 90mg/d conjunction 2mg/d copper ALS patient .</brief_summary>
	<brief_title>Safety Study High Doses Zinc ALS Patients</brief_title>
	<detailed_description>Physicians Phoenix Neurological Associates ( PNA ) look individual diagnose ALS participate open label phase II safety trial zinc conjunction copper , use combination Riluzole treating ALS . This investigator initiate trial conduct Drs . Todd Levine David Saperstein help determine zinc give high dos safe tolerate could possibly slow progression ALS . Over fifty year ago epidemic ALS discover Island Guam disease complex ALS find one hundred time prevalent rest world . Research ALS Guam link ALS , along Parkinson 's Disease Dementia , neurotoxin , Î²-methylamino-L-alanine ( BMAA ) . BMAA non-essential amino acid produce cyanobacterium find large concentration food consume people Guam . Subsequently several group identify high concentration BMAA brain tissue patient North America Europe several neurodegenerative disease include ALS , Parkinson 's Disease Alzheimer 's Diseases . A small proportion ALS , ( 2 % ) , associate mutation superoxide dismutase ( SOD1 ) gene . Mice express mutant gene exhibit progressive , ALS-like neurodegenerative disease.Since know SOD1 bind zinc , many mutant form enzyme associate ALS show altered zinc binding , zinc may play key role pathological process associate ALS . Previous study show ALS mutant G93A SOD transgenic mouse , actual zinc supplementation delay death . Zinc also think serve endogenous antioxidant central nervous system help protect BBB oxidative stress prevent BMAA cross brain . It demonstrate BMAA bind exceptionally strongly transition metal ion zinc , copper , nitrogen . If BMAA cross permeable BBB , enters compartment glutamate bound zinc , glutamate/zinc complex would dissociate favor zinc strong affinity BMAA . This could lead high level unbound glutamate believe highly neurotoxic ALS patient . We hypothesize expose patient high level zinc , BMAA glutamate would keep bound complex zinc , i.e . eliminate competitive binding zinc , lead less excitotoxic free glutamate glutamate toxicity would reduce .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>1 . Age 1885 2 . Male Female 3 . Clinically definite probable ALS El Escorial criterion 4 . ALSFRS &gt; 25 5 . If Riluzole must stable dose least 30 day prior screen 6 . Capable provide informed consent comply trial procedure 1 . Patients FVC 50 % 2 . History liver disease 3 . Severe renal failure 4 . Creatinine great equal 1.5 mg/dL 5 . History intolerance zinc copper 6 . Evidence motor neuron disease great 5 year 7 . Any comorbid condition would make completion trial unlikely 8 . If female , pregnant breastfeeding ; , childbearing age , unwillingness use birth control . 9 . Any trial medication . Nontrial medication cause exclusion 10 . Patient history significant anemia 11 . Elevated level zinc baseline 12 . Patients copper level normal baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>ALS treatment</keyword>
	<keyword>Zinc</keyword>
	<keyword>Copper</keyword>
	<keyword>BMAA</keyword>
	<keyword>ALS</keyword>
</DOC>